leukemia
Biomea Fusion Receives FDA Clearance to Begin Phase I Trial of BMF-219
The company will study the selective irreversible menin inhibitor in relapsed or refractory AML patients who harbor MLL/KM2TA gene rearrangements or NPM1 mutations.
Syros Pharmaceuticals Begins Phase II Trial of Tamibarotene Triplet Regimen in RARA-Positive AML
The company will explore the activity of tamibarotene, plus venetoclax and azacitidine in RARA-positive newly diagnosed, unfit acute myeloid leukemia patients.
BioCure Technology to Develop ROR1-Targeted CAR T-Cell Therapy
The company will develop a novel CAR T-cell therapy platform, focusing on the chronic lymphocytic leukemia and solid tumor markets.
Gilead Sciences Q2 Revenues Grow 21 Percent as CAR T-Cell Business Jumps 39 Percent
Revenues from pharmaceutical products were almost entirely driven by the COVID-19 treatment remdesivir, though sales of Kite Pharma's CAR T-cell therapies grew, too.
Aveo Oncology's Ficlatuzumab Improves Response, Survival for AML Patients, Study Finds
The study also identified high HGF expression and p-S6 suppression as biomarkers of resistance and response, respectively.